報價延遲最少15分鐘:2024/12/24 13:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.02/-5.32
|
|
企業價值
65.04M
|
| 資產負債 |
|
每股賬面淨值
10.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities. |